African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.

Slides:



Advertisements
Similar presentations
Stop TB Strategy Planning Frameworks Mukund Uplekar TB Strategy, Operations and Health Systems, Stop TB Department, WHO.
Advertisements

Global Measles and Rubella Strategic Plan
From DOTS to the Stop TB Strategy Building on Achievements for Future Planning Stop TB Partnership Symposium at the 37 th UNION World Conference on TB.
Overview of the Global Fund: Guiding Principles Grant Cycle / Processes & Role of Public Private Partnerships Johannesburg, South Africa Tatjana Peterson,
TB and poverty agenda in WPR WHO/WPRO Stop TB. World Health Organization Percentage of population living below US$1 a day.
The U.S. President’s Emergency Plan for AIDS Relief The Evolving HIV Prevention Strategy for IDUs in PEPFAR Amb. Eric Goosby US Global AIDS Coordinator.
TB and HIV: Tightly Linked… and Why We Should Care.
Almost 14 years ago all countries endorsed a set of 8 Millennium Development Goals (or MDGs). 3 of those 8 Goals focus on health – that being child mortality,
Technical Advisory Group meeting, WHO/WPRO
Global Plan to Stop TB Stop TB Partnership
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
The Global Plan to Stop TB, (1)
1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.
Tools for HIV/TB Integration and the Civil Society Experience Carol Nawina Nyirenda Executive Director Community Initiative for Tuberculosis, HIV/AIDS.
African Business Leaders on Health GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 2010 Technical Assistance.
Departmental Perspectives on Viral Hepatitis
PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,
THE FIGHT TO STOP TB WHAT ARE WE FIGHTING? TUBERCULOSIS: THE WORLD’S NO. 1 KILLER AMONG CURABLE, INFECTIOUS DISEASES But there is hope PEOPLE WHO HAVE.
Framework and Standards for Effective TB Control Module 3 – March 2010
Bi-State TB Elimination April 10, 2014 Anna Frye Michelle Goodyear Tuberculosis: Recent Trends and Relevant Research.
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
COUNTRY ACTION: SUSTAINABLE INVESTMENT STOP TB PARTNERSHIP FORUM STOP TB PARTNERSHIP FORUM 24TH-26TH MARCH TH-26TH MARCH 2004 BY BY MRS NENADI USMAN.
1 |1 | Key problems Neglected Tropical Diseases Hidden and silent : Key problems Complacency, lack of information and commitment Complacency, lack of information.
Prevention and Control of Viral Hepatitis Infection: WHO Framework for Global Action Prevention and Control of Viral Hepatitis Infection: WHO Framework.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Session 11: MDR & XDR-TB: How Can Business Help Stem the Tide?
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
Missed opportunities to diagnose TB and HIV Co-infection in HIV workplace program Dr Fred Mugyenyi Asiimwe Medical Director, ALAFA.
R&D for TB: Updates & Opportunities for the Private Sector Christian Lienhardt Senior Scientific Advisor, Stop TB Partnership WHO, Geneva GBC Conference.
Investing in Youth: Population, Health and Social Challenges UNFPA Mexico October 2004.
World Bank Seminar Series: Global Issues Facing Humanity Diseases without borders.
Update of the Global Plan to Stop TB TB/HIV Working Group Meeting Geneva, November 2009 Christian Lienhardt.
End TB Strategy HCW with cough since January. Seen at government clinic thrice with no sputum/CXR. Diagnosed TB in May only.
Universal access to TB care what is the challenge, what policy, what is being implemented Cancun 3 December 2009 Léopold BLANC and TBS team TBS/STB/WHO.
INAT and Research Christian Lienhardt Stop TB Partnership Geneva First Meeting of the Core Group of the Subgroup on Introducing New Tools and Approaches.
1 [INSERT SPEAKER NAME DATE & LOCATION HERE] Ethics of Tuberculosis Prevention, Care and Control MODULE 2: BACKGROUND ON TUBERCULOSIS Insert country/ministry.
Proposed Post-2015 Global Tuberculosis Strategy and Targets Dr Mario Raviglione Director, Global TB Programme World Health Organization, Geneva, Switzerland.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
WHO/OMS Improving and increasing investments in the health outcomes of the poor Macroeconomics and Health in context Dr. Sergio Spinaci, WHO Senegal, February.
MILLENIUM DEVELOPMENT GOALS Board review Notes Dr. Theresita R. Lariosa.
Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva, Switzerland TB prevention, care and control, : Framing global and WHO strategic.
Moving ahead with the Stop TB Strategy: where are we today? Dr Mario Raviglione Director, WHO Stop TB Department Joint Meeting of Core Teams and High Burden.
Regional Videoconference Addressing Stigma and Discrimination of HIV/AIDS in Africa Thursday, April 2, 2009 UNAIDS Perspective Susan Timberlake, Senior.
Meeting of the Working Group on TB Drug Development Why you need to be engaged? Marcos Espinal Executive Secretary Stop TB Partnership 29 October 2004.
Country Office for Bangladesh Towards reaching the Millennium Development Goals Dr Erwin Cooreman Medical Officer (TB) WHO-Bangladesh.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
MDG 6: Combat HIV/AIDS and other diseases. Where are we…  Regionally, “on track” for MDG-6 (only a few countries are progressing slowly or show no progress)
Dr Ral Antic Chair Scientific Committee IUATLD-APR Australia Pre-Conference Workshop 1 National TB Control Program Summary & Remarks.
The Bank’s Regional HIV/AIDS Strategies An Overview.
THE GLOBAL FUND SUSTAINING THE GAINS AND IMPACT Uganda November 2013.
Global Tuberculosis Control 2007 Did we reach the 2005 targets? Will we achieve the Millennium Development Goals?
2007 Pan American Health Organization 2004 Pan American Health Organization Malaria in the Americas: Progress, Challenges, Strategies and Main Activities.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
World Health Organization
financial requirements
INTERNATIONAL PLANNED PARENTHOOD FEDERATION - AFRICA REGION (IPPFAR)
Prisons and TB in Europe
GARD/NCD Action Plan & 2011 UN Summit on NCDs
Progress in Implementing collaborative TB/HIV activities
TUBERCULOSIS, TB/HIV & MDR-TB
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
Pre-conference Meeting Report
Knowledge gaps in formulating TB Control Policies for Prisons
Key issues in DOTS implementation
Update on HIV and TB situation in SEAR Dr Mukta Sharma RA HIV TB HEP WHO SEARO Global Fund , South-East Asia Constituency Meeting, April 2018,
5th DEWG meeting Conclusions
The STOP TB Strategy – 2009 VISION: A TB-free world
A Time of Commitments and Actions to accelerate action to End TB
5th edition NTP MANUAL OF PROCEDURES Chapter 1: Introduction
Presentation transcript:

African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global TB: the Problem, Progress to date and future challenges Paul Nunn, WHO

Contents  The state of global TB  Goals, targets and achievements  WHO's role in addressing TB  Possible roles of business in addressing TB

Estimated number of cases Estimated number of deaths 1.8 million (range 1.6–2.3 million) 9.4 million (range 8.9–9.9 million) 440,000 ( million) All forms of TB Multidrug-resistant TB (MDR-TB) HIV-associated TB 1.4 million (15%) (1.3–1.6 million) 520,000 (0.45–0.62 million) 150,000 (0.05–0.27 million) The Global Burden of Tuberculosis, 2008

Estimated TB incidence rates, % of cases and 98% of deaths are in developing countries Africa 31% West Pacific 20% SE Asia 34% Europe 5% East Mediterranean 7% Americas 3%

Why TB is a business problem  1% of South Africa's population gets TB each year  Other countries in Southern Africa about the same

The goals of TB care and control  Save the lives and health of those with TB  Prevent transmission of infection

TB Control Global Targets 2015: Goal 6: Combat HIV/AIDS, malaria and other diseases Target 8: to have halted by 2015 and begun to reverse the incidence… Indicator 23: incidence, prevalence and deaths associated with TB Indicator 24: proportion of TB cases detected and cured under DOTS 2015: 50% reduction in TB prevalence and deaths by : elimination (<1 case per million population)

Achievements thus far 36 million patients cured, million deaths averted compared to 1995 care standards Mortality reduced by 35% since 1990 Cure rates >85% 50% prevalence and mortality targets on track except Africa MDG achieved: global TB incidence peaked in 2004 But…. TB incidence declining too slowly, case detection stagnating, and MDR-TB care only now starting scale-up

Year Incidence/million/yr Elimination 16%/yr Global Plan 6%/yr Current trajectory 1%/yr Full implementation of Global Plan: 2015 MDG target reached but TB not eliminated by 2050 Elimination target: 1 / million / year by 2050 TB incidence 10x lower than today, but >100x higher than elimination target in 2050 Current rate of decline

WHO core functions in global TB control and research 1.Development of policy, norms and standards 2.Technical support to countries and its coordination 3.Monitoring & evaluation 4.Fostering partnerships including with civil society 5.Promoting research Focus on key priorities in each area given constrained resources

The global response: Stop TB Strategy & Global Plan To save lives, prevent suffering, protect the vulnerable, & promote human rights 1.Pursue high-quality DOTS expansion 2.Address TB-HIV, MDR- TB, and needs of the poor and vulnerable 3.Contribute to health system strengthening 4.Engage all care providers 5.Empower people with TB and communities 6.Enable and promote research

What are the challenges in 2010 to reach elimination? 1.Core TB business: quality variable and funding not secure 2.Case detection: still 63%, late diagnosis 3.TB/HIV impact in Africa: progress but not enough 4.MDR-TB in former USSR, China etc: very slow response 5.Health policies, systems and services: weak, no UHC 6.Socio-economic determinants and risk factors: how to tackle? 7.Non-state practitioners: low standards, irrational drug use 8.Communities: un-aware, un-involved, not mobilised 9.Research: finally new diagnostics, but underfunded

Close NTP funding gaps Provide free services, ensure quality drugs, regulate private care, better M&E, collaboration on co-morbidities Reduce costs to patients to minimise impoverishment Secure political commitment and civil society awareness & mobilization Socio-economic factors: living conditions, food insecurity, awareness, risk behaviour, access to care Innovative action needed in 4 spheres "Moving beyond the TB box" Early & increased case detection Scale-up TB/HIV and MDR-TB interventions M&E and impact measurement Engage all care providers and communities Active screening among at-risk populations Introduction of modern technology Target new tools Operational research and transfer of technology

Possible roles of business in  TB care, prevention and control  Work-force TB diagnosis and care programmes to increase case detection  TB screening in high risk workforce, eg mining  Corporate support of national or local TB control programmes  Private provision of diagnosis, care, prevention etc  Pathfinders in introduction of new, proven technologies

Possible roles of business in  TB and the development agenda  Advocate with government for political commitment to TB  Help mobilise civil society, including private sector  Fight stigma  Health policies and systems  Ensure regulated quality of drug manufacture, provision of private care

Possible roles of business in  Research and development  Develop new drugs, diagnostics and vaccines  Engage collaboratively with others in eg development of multi-drug regimens

Conclusion  Building on successes to date, WHO and the Stop TB Partnership are open to supporting business to do more to stimulate better TB care, prevention and control